Medications work for severely addicted smokers: Implications for addiction therapists and primary care physicians

References 

1. Anton R. Current pharmacotherapies of alcoholism: a U.S. perspective. The American Journal on Addictions. 2003;12(Suppl 1):S53–S68
2. Fiellin D, Kleber HD, Trumble-Hejduk J, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment. 2004;
3. Fiore MC, Baily WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2000;
4. Hymowitz N, Sexton M, Ockene J, Grandits G. Baseline factors associated with smoking cessation and relapse. Preventive Medicine. 1991;20:590–601
5. Jaffe JH, O’Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug and Alcohol Dependence. 2003;70:S3–S11
   • Abstract
   • Full Text
   • Full-Text PDF (197 KB)
   • CrossRef
6. National Cancer Institute. Changes in cigarette-related disease risks and their implication for prevention and control. National Cancer Institute Monograph 8. National Institutes of Health Publication No. 97–4213. 1997;
7. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Journal of the American Medical Association. 1991;266:3133–3138
8. U.S. Department of Health and Human Services. The health consequences of smoking: nicotine addiction. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1988;
9. U.S. Department of Health and Human Services. Reducing tobacco use: a report from the surgeon general. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2000;